In a hypotensive, tachycardic alcoholic with a bleeding 2‑cm duodenal ulcer, platelet count 53 ×10⁹/L, INR 1.8, normal APTT and fibrinogen, and thromboelastography showing a slightly shortened reaction time with otherwise normal clot kinetics, which is the most appropriate next step: administer factor VIIa, administer prothrombin complex concentrate, consult interventional radiology for embolization, or consult surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Consult Surgery for Definitive Intervention

In this hypotensive, tachycardic patient with a large (2 cm) duodenal ulcer with visible clot, ongoing hemodynamic instability despite resuscitation, and endoscopic intervention deemed difficult, surgical consultation is the most appropriate next step.

Clinical Reasoning

This patient presents with high-risk features for rebleeding and mortality:

  • Large ulcer size (2 cm) - significantly increases rebleeding risk
  • Persistent hemodynamic instability (BP 90/50, HR 110) despite 3 units PRBCs, plasma, and platelets
  • Visible clot that was not treated endoscopically due to technical difficulty
  • Forrest classification likely IIa or IIb (visible vessel or adherent clot) - carries 40-50% rebleeding risk without definitive therapy

The 2021 ACG guideline recommends endoscopic therapy for ulcers with active bleeding and nonbleeding visible vessels 1. However, when endoscopic hemostasis is not achieved or is technically unfeasible, as explicitly stated in this case, escalation is mandatory.

Why Surgery Over Other Options

Interventional Radiology (Option C)

The ACG guideline suggests transcatheter embolization specifically after failed repeat endoscopy for recurrent bleeding 1. This patient hasn't had adequate initial endoscopic therapy - the clot was visualized but not treated. IR embolization is a salvage option when endoscopy has been attempted and failed, not as a primary intervention when endoscopy was incomplete.

Factor VIIa (Option A)

Recombinant factor VIIa is not indicated here. The patient's thromboelastography shows normal clot kinetics - normal kinetic time, maximum amplitude, and alpha angle indicate adequate fibrin polymerization and platelet function 2. Factor VIIa is reserved for life-threatening coagulopathic bleeding unresponsive to conventional therapy, not for anatomic bleeding with near-normal coagulation parameters 3.

Prothrombin Complex Concentrate (Option B)

PCC reverses vitamin K antagonist effects and corrects deficiencies of factors II, VII, IX, and X 4. While this patient has an INR of 1.8 (likely from liver disease in an alcoholic), the TEG demonstrates normal thrombin generation (slightly shortened reaction time actually suggests hypercoagulability, not hypocoagulability). The coagulopathy is mild and already partially corrected with 1 unit FFP. PCC carries thrombotic risk 4 and won't address the anatomic bleeding source - a large ulcer with untreated visible clot.

The Critical Issue: Unreliable Hemostasis

A 1999 study on duodenal ulcer bleeding established that unreliable hemostasis predicts 90% rebleeding probability and warrants urgent surgery 5. This patient has:

  • Large ulcer (2 cm)
  • Visible clot not treated
  • Persistent shock despite resuscitation
  • Technical difficulty precluding endoscopic therapy

These factors collectively indicate unreliable hemostasis requiring surgical intervention.

Surgical Approach

Surgery should perform:

  • Duodenotomy with ulcer oversewing or excision
  • Ligation of the gastroduodenal artery (the typical bleeding source in posterior duodenal ulcers)
  • Consider vagotomy and pyloroplasty or highly selective vagotomy depending on ulcer location and patient stability

Management of Coagulopathy

The mild coagulopathy (INR 1.8, platelets 53K, fibrinogen 200) should be corrected perioperatively:

  • Platelet transfusion to >50 × 10⁹/L for surgery 6
  • Additional FFP if INR remains >1.5-1.8 before incision
  • Fibrinogen concentrate if levels drop <1.5-2.0 g/L intraoperatively 3, 7

The normal TEG parameters suggest these modest laboratory abnormalities are not driving the bleeding - the anatomic lesion is.

Common Pitfalls

  • Waiting for repeat endoscopy when initial endoscopy was inadequate and patient remains unstable
  • Over-relying on factor concentrates for what is fundamentally an anatomic bleeding problem
  • Delaying surgery in high-risk ulcers with unreliable hemostasis - mortality increases with each rebleeding episode
  • Assuming IR is always preferable to surgery - IR is for failed endoscopy after adequate attempts, not as primary therapy

The definitive answer is D: Consult for surgical intervention. This patient requires anatomic control of bleeding that endoscopy could not provide.

Related Questions

What are the differences in management between acute and chronic gastrointestinal (GI) bleeding?
How long does it take to recover the red blood cell count after a gastrointestinal (GI) bleed stops?
In a septic patient with acute kidney injury, severe metabolic acidosis, and a disseminated intravascular coagulation (DIC) score of 5, is therapeutic anticoagulation indicated?
Does a patient with rectal bleeding, thrombocytopenia, elevated D-dimer, low fibrinogen, prolonged PT, and severe anemia with concern for DIC qualify for FFP or other replacement therapies in addition to platelet transfusion?
In a 44-year-old woman recently discharged after an upper gastrointestinal bleed with erosive gastropathy, low hemoglobin (~8 g/dL), and markedly elevated C‑reactive protein, who now presents with persistent weakness, abdominal pain, CRP 297 mg/L, leukocytosis 18 ×10⁹/L, hemoglobin 8.2 g/dL, TSH 87 mIU/L, and a normal abdominal CT, what further management should the family physician undertake?
How should I manage right jaw and lip numbness in a patient with metastatic breast cancer on Tagrisso (osimertinib) who has right frontal brain lesions with skull bone involvement treated with stereotactic body radiation therapy (SBRT)?
What is the clinical significance and recommended management of a low serum testosterone level (7 ng/dL) measured by liquid chromatography in a female?
Can buspirone (Buspar) be used to treat obsessive‑compulsive disorder, and what is the appropriate dosing regimen?
What are the recommended treatment options for bipolar II disorder?
Is a testosterone level of 7 ng/dL considered low for a woman given the reference range of 4–50 ng/dL?
Is albumin therapy appropriate for patients with liver failure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.